

# Jeffrey A Longmate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2811401/publications.pdf>

Version: 2024-02-01

65  
papers

4,780  
citations

109321

35  
h-index

106344

65  
g-index

65  
all docs

65  
docs citations

65  
times ranked

5569  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic control of susceptibility to murine systemic lupus erythematosus. <i>Immunity</i> , 1994, 1, 219-229.	14.3	476
2	Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. <i>Journal of the American College of Cardiology</i> , 1999, 33, 304-310.	2.8	331
3	Speed congenics: a classic technique in the fast lane (relatively speaking). <i>Trends in Immunology</i> , 1997, 18, 472-477.	7.5	301
4	Bacteria-Induced Intestinal Cancer in Mice with Disrupted Gpx1 and Gpx2 Genes. <i>Cancer Research</i> , 2004, 64, 962-968.	0.9	282
5	Manganese Superoxide Dismutase-Mediated Gene Expression in Radiation-Induced Adaptive Responses. <i>Molecular and Cellular Biology</i> , 2003, 23, 2362-2378.	2.3	263
6	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 777-783.	2.3	261
7	The Immunohistochemical Diagnostic Panel for Epithelial Mesothelioma. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1409-1419.	3.7	174
8	Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. <i>Blood</i> , 2009, 113, 6465-6476.	1.4	140
9	Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma. <i>Cancer</i> , 2004, 100, 2125-2131.	4.1	118
10	Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. <i>PLoS Pathogens</i> , 2014, 10, e1004524.	4.7	106
11	Predominant type 1 CMV-Specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. <i>Human Immunology</i> , 2004, 65, 476-485.	2.4	100
12	The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. <i>Clinical Cancer Research</i> , 2005, 11, 4444-4450.	7.0	97
13	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 19-26.	2.3	93
14	Gender Influences Herpes Simplex Virus Type 1 Infection in Normal and Gamma Interferon-Mutant Mice. <i>Journal of Virology</i> , 2001, 75, 3048-3052.	3.4	92
15	Multiplex inheritance of component phenotypes in a murine model of lupus. <i>Mammalian Genome</i> , 1999, 10, 176-181.	2.2	91
16	Complexity and Power in Case-Control Association Studies. <i>American Journal of Human Genetics</i> , 2001, 68, 1229-1237.	6.2	91
17	Relative dominance of HLA-B*07 restricted CD8+ T-Lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. <i>Human Immunology</i> , 2003, 64, 440-452.	2.4	90
18	Longitudinal Assessment of Cytomegalovirus (CMV)-Specific Immune Responses in Liver Transplant Recipients at High Risk for Late CMV Disease. <i>Journal of Infectious Diseases</i> , 2007, 195, 633-644.	4.0	87

#	ARTICLE	IF	CITATIONS
19	Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304.	4.0	86
20	The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 433-437.	1.9	85
21	Evidence for X-Chromosomal Schizophrenia Associated with microRNA Alterations. <i>PLoS ONE</i> , 2009, 4, e6121.	2.5	84
22	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. <i>Anti-Cancer Drugs</i> , 2009, 20, 179-184.	1.4	82
23	A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2013, 87, 1322-1332.	3.4	81
24	CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. <i>Journal of Immunology</i> , 2003, 170, 3401-3407.	0.8	80
25	Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel. <i>Clinical Cancer Research</i> , 2004, 10, 461-467.	7.0	73
26	Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus. <i>Journal of Virology</i> , 2004, 78, 3965-3976.	3.4	69
27	MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , 2017, 129, 114-125.	1.4	69
28	A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 1556-1563.	7.0	63
29	Programmed Death-1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 25-33.	4.0	63
30	Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors. <i>Cancer Research</i> , 2004, 64, 5407-5414.	0.9	48
31	Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2011, 85, 2878-2890.	3.4	47
32	Functional Comparison of T Cells Recognizing Cytomegalovirus pp65 and Intermediate-Early Antigen Polypeptides in Hematopoietic Stem-Cell Transplant and Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2006, 194, 1410-1421.	4.0	45
33	Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. <i>Blood</i> , 2004, 104, 847-856.	1.4	42
34	Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 317-322.	1.3	38
35	Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. <i>Vaccine</i> , 2005, 23, 3453-3468.	3.8	37
36	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), Tj ETQq0 0 0 rgBT /Overlock 1 <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 835-843.	2.3	35

#	ARTICLE	IF	CITATIONS
37	Simultaneous Reconstitution of Multiple Cytomegalovirus-Specific CD8+Cell Populations with Divergent Functionality in Hematopoietic Stem-Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2005, 191, 977-984.	4.0	28
38	Variations of dose and electrode spacing for rat breast cancer electrochemical treatment. <i>Bioelectromagnetics</i> , 2001, 22, 205-211.	1.6	27
39	Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge. <i>Journal of Immunology</i> , 2003, 171, 4028-4039.	0.8	27
40	Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder. <i>Neuroscience Letters</i> , 2010, 486, 136-140.	2.1	27
41	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , 2006, 1, 126-134.	1.1	27
42	Cytomegalovirus Immune Reconstitution Occurs in Recipients of Allogeneic Hematopoietic Cell Transplants Irrespective of Detectable Cytomegalovirus Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 890-902.	2.0	26
43	Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy Maintain Activated CD8+T Cell Subsets as a Strong Adaptive Immune Response to Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2001, 184, 256-267.	4.0	25
44	In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. <i>Experimental Hematology</i> , 2006, 34, 497-507.	0.4	22
45	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. <i>Transplant International</i> , 2011, 24, 920-931.	1.6	22
46	Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up. <i>Gynecologic Oncology</i> , 2000, 77, 433-438.	1.4	20
47	Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 22-28.	2.3	19
48	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 33-37.	2.6	18
49	Relevance of Peptide Avidity to the T Cell Receptor for Cytomegalovirus-Specific Ex Vivo CD8 T Cell Cytotoxicity. <i>Journal of Infectious Diseases</i> , 2003, 188, 908-918.	4.0	17
50	Toxicity equivalence range design (TEQR): A practical Phase I design. <i>Contemporary Clinical Trials</i> , 2011, 32, 114-121.	1.8	17
51	Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray. <i>Mammalian Genome</i> , 2004, 15, 199-209.	2.2	14
52	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. <i>Blood</i> , 2011, 118, 2159-2169.	1.4	14
53	Improved Hepatic Toxicity Profile of Portal Vein Adjuvant Hepatic Infusional Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 4876-4880.	1.6	11
54	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. <i>Journal of Thoracic Oncology</i> , 2006, 1, 126-34.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II California Cancer Consortium Trial. <i>Clinical Lung Cancer</i> , 2004, 6, 102-107.	2.6	10
56	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 210-216.	1.0	10
57	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 327-332.	2.3	9
58	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 353-359.	2.3	9
59	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 283-289.	2.3	9
60	A phase II trial of gefitinib and pegylated IFN- $\gamma$ in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 494-9.	2.2	9
61	Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up. <i>Gynecologic Oncology</i> , 1999, 75, 419-426.	1.4	8
62	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). <i>Clinical Lung Cancer</i> , 2021, 22, 541-548.	2.6	8
63	Three Ways of Combining Genotyping and Resequencing in Case-Control Association Studies. <i>PLoS ONE</i> , 2010, 5, e14318.	2.5	7
64	Loss of T Cell Progenitor Checkpoint Control Underlies Leukemia Initiation in Rag1-Deficient Nonobese Diabetic Mice. <i>Journal of Immunology</i> , 2013, 190, 3276-3288.	0.8	5
65	Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology. <i>Current Problems in Cancer</i> , 2020, 44, 100583.	2.0	4